Collegium Pharmaceutical, Inc.

NasdaqGS COLL

Collegium Pharmaceutical, Inc. Total Assets for the quarter ending September 30, 2024: USD 1.64 B

Collegium Pharmaceutical, Inc. Total Assets is USD 1.64 B for the quarter ending September 30, 2024, a 38.86% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.
  • Collegium Pharmaceutical, Inc. Total Assets for the quarter ending September 30, 2023 was USD 1.18 B, a -1.95% change year over year.
  • Collegium Pharmaceutical, Inc. Total Assets for the quarter ending September 30, 2022 was USD 1.20 B, a 61.89% change year over year.
  • Collegium Pharmaceutical, Inc. Total Assets for the quarter ending September 30, 2021 was USD 741.80 M, a 15.21% change year over year.
  • Collegium Pharmaceutical, Inc. Total Assets for the quarter ending September 30, 2020 was USD 643.84 M, a 111.81% change year over year.
Key data
Date Total Assets Current Liabilities Total Non-Current Liabilities Shareholders' Equity
Market news
Loading...
NasdaqGS: COLL

Collegium Pharmaceutical, Inc.

CEO Mr. Vikram Karnani
IPO Date May 7, 2015
Location United States
Headquarters 100 Technology Center Drive
Employees 197
Sector Health Care
Industries
Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

EOLS

Evolus, Inc.

USD 9.47

-3.37%

RGC

Regencell Bioscience Holdings Limited

USD 4.86

-4.71%

ALKS

Alkermes plc

USD 28.50

0.53%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

AMPH

Amphastar Pharmaceuticals, Inc.

USD 38.48

1.48%

PROC

Procaps Group S.A.

USD 1.76

7.98%

StockViz Staff

January 15, 2025

Any question? Send us an email